Publicly-available genetic databases promote data sharing and fuel scientific discoveries for the prevention, treatment, and management of disease. In 2018, we built Color Data, a user-friendly, open access database containing genotypic and self-reported phenotypic information from 50,000 individuals who were sequenced for 30 genes associated with hereditary cancer. In a continued effort to promote access to these types of data, we launched Color Data v2, an updated version of the Color Data database. This new release includes additional clinical genetic testing results from more than 18,000 individuals who were sequenced for 30 genes associated with hereditary cardiovascular conditions, as well as polygenic risk scores for breast cancer, coronary artery disease, and atrial fibrillation. In addition, we used self-reported phenotypic information to implement the following four clinical risk models: Gail Model for five-year risk of breast cancer, Claus Model for lifetime risk of breast cancer, simple office-based Framingham Coronary Heart Disease Risk Score for ten-year risk of coronary heart disease , and CHARGE-AF simple score for five-year risk of atrial fibrillation.
INTRODUCTION
The use of next generation sequencing (NGS) technologies in research and clinical laboratories has led to a rapid increase of genetic data. However, there is a lack of publicly-available genetic data, especially paired genotypic-phenotypic data. In 2018, we launched Color Data, an open-access, cloud-based database containing genotypic and self-reported phenotypic information from 50,000 individuals who were sequenced for 30 genes associated with hereditary cancer (1) . Color Data has already made an impact on the scientific community, being utilized in peer-reviewed publications (2, 3) and presented as a resource to educators (4) .
Its user-friendly interface enables researchers to easily execute their own queries with self-serve filters and displays the results as text, tables, and graphs. Results can also be downloaded in different files formats for further analyses and shared via email or social media.
Another important consideration when designing and implementing the database was scalability for volume and integration of different data points. For the second release of Color Data (Color Data v2), we added new features to the existing hereditary cancer dataset as well as a new dataset of genotypic and self-reported phenotypic information related to hereditary cardiovascular conditions from more than 18,000 individuals. Importantly, the hereditary cardiovascular conditions dataset retains the same user-friendly interface, making it easy for researchers and scientists to explore a new disease area.
Here we describe updates made to the database, including changes to the cohort and the addition of new query filters and results such as family health history. We also added clinical risk models to Color Data v2, such as the Gail Model (5) and the Claus Model (6) for breast cancer, simple office-based Framingham Coronary Heart Disease Risk Score (7) for coronary heart disease, and CHARGE-AF simple score (8) for atrial fibrillation. These risk models are commonly used by healthcare providers in the clinic and are important tools to estimate risk.
Recent work has demonstrated that polygenic scores can also accurately predict and stratify risk for common, complex diseases and can identify individuals who have magnitude of risk for disease similar to those with pathogenic or likely pathogenic variants (9, 10) . As such, Color Data v2 also includes polygenic scores for breast cancer, coronary artery disease, and atrial fibrillation (AF). We highlight the addition of the hereditary cardiovascular conditions dataset, clinical risk models, and polygenic scores through two sample queries in the database. To our knowledge, Color Data is the first database to include pre-calculated scores from clinical risk models and for polygenic risk, which can help researchers investigate the relationship between different types of risk factors, both genetic and non-genetic, for disease.
MATERIALS AND METHODS
Design and implementation of the database were previously described in the flagship publication by Barrett, Neben et al. (1) . All individuals included in Color Data v2 received a multi-gene NGS panel test from Color Genomics, Inc. ('Color', Burlingame, CA) for 30 genes associated with hereditary cancer. In addition, a subset of individuals also received multi-gene NGS panel testing for 30 genes associated with hereditary cardiovascular conditions. All individuals consented to have their genetic and self-reported phenotypic information appear in Color's research database.
Laboratory procedures, bioinformatics analysis, and variant interpretation for the multi-gene panel tests were performed at Color (Burlingame, CA) under Clinical Laboratory Improvements Amendments (#05D2081492) and College of American Pathologists (#8975161) compliance as previously described (11) . Bioinformatics analysis included the previously described 30 genes associated with hereditary cancer and was updated to include an additional 30 genes associated with hereditary cardiovascular conditions: ACTA2, ACTC1, APOB, COL3A1, DSC2, DSG2, DSP, FBN1, GLA, KCNH2, KCNQ1, LDLR, LMNA, MYBPC3, MYH7, MYH11, MYL2, MYL3, PCSK9, PKP2, PRKAG2, RYR2, SCN5A, SMAD3, TGFBR1, TGFBR2, TMEM43, TNNI3, TNNT2, and TPM1 . Analysis, variant calling, and reporting focused on the complete coding sequence and adjacent intronic sequence of the primary transcript(s), unless otherwise indicated. In APOB , exon 1 was not analyzed, and variants of uncertain significance (VUS) were not reported. In MYH7 , VUS were not reported for exon 27. In several genes, certain exons were not analyzed: exons 4 and 14 of KCNH2, exon 1 of KCNQ1, exon 11 of MYBPC3, exon 5 of PRKAG2, and exon 1 of TGFBR1 .
Laboratory procedures and imputation for low coverage whole genome sequencing were performed at Color as previously described (12) . Data from low coverage whole genome sequencing were used to calculate previously published polygenic scores for breast cancer (10) , coronary artery disease (9) , and atrial fibrillation (9) . Each polygenic score was normalized using principal components analysis to account for the effects of population stratification. While polygenic scores have the highest performance in people of European ancestry, recent studies have demonstrated that they have stratification ability across global populations as well (13, 14) .
To note, if users would like to view polygenic risk score results for a given query, they must select 'Calculated' in the polygenic risk score filter because only a subset of the individuals in the database have a calculated polygenic risk score. Individuals who do not have polygenic risk scores calculated are captured under the filter value 'Unknown'. Other self-reported phenotypic and genotypic information from 'Calculated' and 'Unknown' individuals is included in other query results by default, unless otherwise selected.
Genotypic and self-reported phenotypic information were used in the following clinical risk models: Gail Model for five-year risk of breast cancer (5) Table 1 and for hereditary cardiovascular conditions in Table 2 .
RESULTS

Web interface
The Table 2 . The same 'AND' logic and 'OR' logic apply, as described above.
Population characteristics
The Figure 1A) and Caucasian (64.6%) ( Figure 1B) . The average age at testing was 44.2 years ( Figure 1A) , and the majority of individuals reported no personal history of cardiovascular disease and/or events (67.7%, n=178) ( Figure 1C ). Nearly one-third of variants were identified in MYBPC3 (30.5%), followed by LDLR (19.6%), KCNQ1 (8.3%), and PKP2 (8.3%) ( Figure 1D ). Of the 266 pathogenic or likely pathogenic variants identified, the most common variant was MYBPC3 c.3628-41_3628-17del (n=38) ( Figure 1E ), which is associated with hypertrophic cardiomyopathies and found at high frequencies (from 2-8%) in Indian populations (16 Figure 1F ). Of those who provided information about their personal history (n=29), no one reported having a personal history of cardiovascular disease and/or events ( Figure 1G ). Taken together, researchers could use this data to better characterize the prevalence of hereditary cardiovascular disorders in a younger, unaffected population to identify asymptomatic individuals who are at risk for future cardiovascular disease and/or events.
Sample query 2: monogenic and polygenic breast cancer risk in women with a personal history of breast cancer
Breast cancer is a common, complex disease that is associated with rare pathogenic and likely pathogenic variants ('monogenic risk') and the cumulative effect of many common changes across the genome ('polygenic risk') (9, 10) . Recent work has suggested that monogenic risk and polygenic risk interact to modify an individual's overall risk for disease (17) (18) (19) (Figure 2A ).
The majority of individuals are Caucasian (73.9%) ( Figure 2B) , with an average age of 59.9
years old at the time of genetic testing (Figure 2A) . The average age of diagnosis for breast cancer was 53.2 ± 11.2 years (standard deviation), and 39.2% of females were less than 50 years old at the time of diagnosis ( Figure 2C ). The pathogenic frequency in this population was 13.3% (Figure 2A) . A total of 82,677 variants were identified, with the majority of variants in BRCA2 (14.6%), BRCA1 (12.0%), and ATM (11.3%) ( Figure 2D ). Compared to the normal distribution of risk scores among all individuals in the dataset (in blue), the distribution in women with a personal history of breast cancer is left-skewed (in red) ( Figure 2E ). T aken together, users could use this data to investigate the risk conferred by monogenic and polygenic risk factors in women with a history of breast cancer.
DISCUSSION
In Color Data v2, we added new query filters and results such as family health history as well as clinical risk models and a polygenic score for breast cancer to the existing hereditary cancer dataset. Overall, the total number of individuals in this dataset increased to 54,000, however, the individuals in Color Data v1 are not a strict subset of the individuals in Color Data v2. This is due to a difference in inclusion criteria between the two versions. In Color Data v1, individuals were included in the database if they had received clinical genetic testing for all or any subset of the 30 hereditary cancer genes. In Color Data v2, individuals were only included if they received genetic testing for all 30 genes. This change in cohort composition likely contributed to the observed change in frequency of pathogenic and likely pathogenic variants in the total population and the increase in the number of total and unique variants.
Database users can also now explore a new disease area with self-reported phenotypic information and genetic data for 30 genes associated with hereditary cardiovascular conditions from 18,738 individuals. The frequency of pathogenic and likely pathogenic variants in our dataset was higher than previously reported estimates (20, 21) . This could be due to the generally younger age of individuals in the cohort and/or reduced penetrance in asymptomatic carriers. Genetic testing for hereditary cardiovascular conditions at population-scale has only recently begun, and sharing results through genetic databases such as Color Data will help rapidly advance our understanding of cardiovascular disease risk. Coronary artery disease may be of particular interest given the influence lifestyle modifications have been shown to have on lowering risk for disease. In a prospective study of more than 55,000 individuals, it was found that a healthy lifestyle was associated with significantly reduced risk of cardiovascular events across all genetic risk groups (22) .
Similar to Color Data v1, Color Data v2 may be limited by selection bias for Caucasians and women, as well as by self-reported phenotypic information. Not all individuals in the database provided enough information to calculate risk for the newly included clinical risk models or had polygenic risk scores calculated, resulting in incomplete datasets. As the field continues to evaluate the personal and clinical utility of polygenic risk scores, it will be important to consider their predictive power in light of other risk factors. In addition, the clinical risk models and polygenic scores shown may change over time as more evidence emerges and novel models are discovered.
DATA SHARING STATEMENT
The data in this report are publicly available at Color Data ( https://data.color.com/ ). All reported variants have been submitted to ClinVar ( https://www.ncbi.nlm.nih.gov/clinvar/submitters/505849/ ). VUS, variant of uncertain significance. *Unknown includes information not reported. † Filter values for "Variant" can only be selected by text typing with autocomplete using HGVS nomenclature. ‡CHARGE-AF ineligible includes individuals less than 46 years or 90 years and older. Framingham ineligibility includes individuals less than 30 years or greater than 74 years. §Unknown includes individuals who did provide enough information to calculate risk scores. ⏀ Only displays normalized risk scores between -3 and 3.
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